Abstract AMP-activated protein kinase (AMPK) serves as a major regulator of energy homeostasis and is activated by different glucose-lowering agents. Indeed, AMPK has been identified as an attractive target for the development of innovative molecules to treat type 2 diabetes. In this issue of Diabetologia
Type 2 diabetes is a leading cause of morbidity and mortality all over the world. Successful management of type 2 diabetes requires strict control of glycaemia and other risk factors to prevent the progression of the disease. Despite the availability of a number of oral glucose-lowering drugs and convenient insulin preparations, the majority of patients fail to maintain tight glycaemic control over time, raising their risk of developing micro-and macrovascular complications. [1] . A key reason for this therapeutic gap may be that current therapies and strategies do not adequately address all of the underlying causes of the disease. If this is the case, it is pivotal to develop further drugs that restore normoglycaemia by targeting specific pathogenic defects [2, 3] .
Type 2 diabetes is accompanied by abnormalities affecting an impressive number of distinct signalling pathways [4, 5] . At present, the discovery of novel molecules targetting these pathways represents a powerful approach for the development of glucose-lowering drug lead compounds. Natural products offer a major resource of biologically active molecules for screening [4, 6] , and active components from plants and marine organisms featuring glucoselowering activity are constantly being identified. Indeed, a large number of natural small molecules have been reported to modulate key signalling pathways involved in type 2 diabetes [4] . These pathways are implicated in insulin signal transduction, insulin secretion, glucose metabolism, peroxisome proliferator-activated receptor regulation, endoplasmic reticulum stress and inflammation and chromatin modification.
AMP-activated protein kinase (AMPK) is a highly conserved serine/threonine protein kinase that serves as a major regulator of energy homeostasis both at the cellular and whole body level [7, 8] . AMPK coordinates a complex network of signalling pathways, ultimately balancing nutrient supply and energy requirements (Fig. 1) . In animal models of insulin resistance and type 2 diabetes, pharmacological activation of AMPK has been shown to improve blood glucose homeostasis, lipid profile and blood pressure [4, 9] and mimics the beneficial effects of physical exercise and energy restriction on these variables. In line with this, AMPK is activated by major glucose-lowering molecules, including the biguanide metformin and the thiazolidinediones [10] , and by the insulinsensitising adipokine adiponectin [10] . These findings have provided a rationale for drug discovery projects aimed at identifying novel AMPK-targeting agents for treating type 2 diabetes and the metabolic syndrome. Targeting AMPK with innovative molecules might present unanticipated difficulties, however, because of unwanted tumour-promoting effects and heart problems [10] . In addition, AMPK activation at the hypothalamic level may cause further undesired consequences, including increased body weight [10] . Thus, development of innovative medicines targeting AMPK must take a number of potential problems into account.
In this issue of Diabetologia, Huang et al. [11] report that the natural dibenzylbutyrolactone-type lignanolide arctigenin, a molecule extracted from the traditional herb Arctium lappa L. (Compositae) that has previously been shown to feature anti-tumour and anti-inflammatory effects [12, 13] , increases AMPK phosphorylation. In addition, they show that arctigenin stimulates glucose uptake in cultured L6 skeletal muscle cells and isolated muscles, while inhibiting gluconeogenesis and lipid synthesis in primary hepatocytes [11] . Interestingly, all of these effects were blocked by AMPKα1/α2 silencing or pharmacological inhibition of AMPK, whereas pharmacological inhibition of phosphoinositide-3 kinase had no effect. Arctigenin also inhibits the respiration of L6 myotubes and of isolated mitochondria through a specific effect on respiratory complex I. Finally, the authors show that chronic administration of arctigenin lowers blood glucose levels and improves lipid metabolism in ob/ob mice, while acute oral administration is effective in inhibiting gluconeogenesis even in wild-type mice. Based on this evidence, they conclude that arctigenin activates AMPK by inhibiting respiratory complex I and improves metabolic derangement in the ob/ob mouse model. The authors suggest that this molecule is of value as a lead compound in drug discovery strategies looking for innovative treatments for type 2 diabetes.
Tang et al., working at the same institution as Huang, recently published an elegant paper showing that arctigenin enhances treadmill endurance in sedentary mice and activates AMPK in C2C12 cultured muscle cells [14] . These authors also concluded that arctigenin might be used as a lead compound for diabetes drug discovery. Thus, the hypothesis that arctigenin research may lead to the identification of agents mimicking the beneficial effects of exercise on metabolic disorders is not a new concept. However, the report by Huang et al. [11] is the first to show a positive effect of arctigenin administration on glucose tolerance and lipid profile in mice. This advance is limited by the lack of in-depth investigation of the mechanisms responsible for the effects of arctigenin. Whether this agent affects in vivo glucose disposal, hepatic gluconeogenesis and insulin secretion and action remains to be conclusively demonstrated. The relative contribution of each of these potential effects also remains to be explored.
Interestingly, it has been reported that arctigenin enhances AMPK phosphorylation and activity through Ca 2+ /calmodulin-dependent protein kinase kinase (CaMKK)-and liver kinase B1 (LKB1)-dependent pathways in C2C12 and H9C2 cells [14] . However, Huang and co-workers [11] found that this mechanism does not occur in the L6 muscle cell line. Instead, arctigenin-induced activation of AMPK occurs indirectly and is not dependent upon LKB1, CaMKK or the nitric oxide synthase cascades. Whether arctigenin exerts differential effects in different muscle cell lines and, maybe more importantly, whether and how its biological action exhibits tissue specificity remain unknown and deserve further attention.
In their paper, Huang et al. report another piece of information that is both puzzling and potentially of interest. In the mouse model, chronic treatment with arctigenin caused a significant reduction in subcutaneous fat with no change in either visceral fat or body weight. The reasons for the differential effect of arctigenin on subcutaneous vs visceral fat were AMPK GPAT HMGR
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Fatty acid synthesis Fig. 1 AMPK-mediated effects of arctigenin on skeletal muscle and liver. Arctigenin-activated AMPK induces glucose uptake (→) and blocks (⊣) fatty acid, sterol and triacylglycerol synthesis. ACC1, acetyl-CoA carboxylase 1; GPAT, glycerol-3-phosphate acyltransferase; HMGR, 3-hydroxy-3-methylglutaryl-CoA reductase not addressed and deserve to be explored in the future, as they might provide novel insight and opportunities for selective modulation of subcutaneous and visceral fat mass in mammals. Why such a significant reduction in subcutaneous fat occurs with no change in total body mass in the arctigenintreated mice also remains a mystery, as does the issue of which tissue(s) compensates in mass for the loss of subcutaneous fat.
Cancer is being increasingly recognised as a major problem in diabetes [15, 16] . Indeed, many forms of cancer show an increased prevalence among diabetic individuals [15, 16] and the clinical outcome of patients with diabetes is often worse [15, 16] . The mechanisms responsible for this association are ultimately unknown and may include molecular abnormalities common to cancer and diabetes. Arctigenin has been identified as an inhibitor of protein kinase B/Akt activation [17] . Recent reports indicate that this feature is key to the known anti-tumour activity of arctigenin [18, 19] . Interestingly, Huang et al. report that chronic administration of arctigenin results in a significant increase in insulinstimulated activation of Akt [11] . Clearly, the effect of arctigenin on Akt deserves to be further investigated as it might shed light onto the molecular mechanisms that determine the impact of diabetes on tumour progression.
In summary, the glucose-lowering properties of Arctium lappa may reveal much about the mechanisms underlying glucose tolerance abnormalities. Whether this information will contribute to the search for innovative glucose-lowering drugs remains unclear. Duality of interest The authors declare that there is no duality of interest associated with this manuscript.
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